Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction

Anesthesiology

Volumn 124, Issue 2, 2016, Pages 353-361

  Evered, Lisbeth ^a   Silbert, Brendan ^a   Scott, David A ^a   Ames, David ^b   Maruff, Paul ^c   Blennow, Kaj ^d  

^a ST VINCENT S HOSPITAL   (Australia)

^b NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMENTIA; ELECTIVE SURGERY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENERAL ANESTHESIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; POSTOPERATIVE COGNITIVE DYSFUNCTION; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPINAL ANESTHESIA; TOTAL HIP PROSTHESIS; COGNITIVE DEFECT; POSTOPERATIVE COMPLICATION; STATISTICS AND NUMERICAL DATA;

AGED; ALZHEIMER DISEASE; BIOMARKERS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS;

EID: 84955674728     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000953     Document Type: Article

References (49)

1. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA, Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators Longitudinal assessment of neurocognitive function after coronary-Artery bypass surgery. N Engl J Med 2001 344 395 402
2. Silbert BS, Scott DA, Evered LA, Lewis MS, Kalpokas M, Maruff P, Myles PS, Jamrozik K, A comparison of the effect of high-And low-Dose fentanyl on the incidence of postoperative cognitive dysfunction after coronary artery bypass surgery in the elderly. A nesthesiology 2006 104 1137 45
3. Moller JT, Cluitmans P, Rasmussen LS, Houx P, Rasmussen H, Canet J, Rabbitt P, Jolles J, Larsen K, Hanning CD, Langeron O, Johnson T, Lauven PM, Kristensen PA, Biedler A, van Beem H, Fraidakis O, Silverstein JH, Beneken JE, Gravenstein JS, Long-Term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet 1998 351 857 61
4. Monk TG, Weldon BC, Garvan CW, Dede DE, van der Aa MT, Heilman KM, Gravenstein JS, Predictors of cognitive dysfunction after major noncardiac surgery. A nesthesiology 2008 108 18 30
5. Evered L, Scott DA, Silbert B, Maruff P, Postoperative cognitive dysfunction is independent of type of surgery and anesthetic. Anesth Analg 2011 112 1179 85
6. Newman MF, Grocott HP, Mathew JP, White WD, Landolfo K, Reves JG, Laskowitz DT, Mark DB, Blumenthal JA, Neurologic Outcome Research Group and the Cardiothoracic Anesthesia Research Endeavors (CARE) Investigators of the Duke Heart Center Report of the substudy assessing the impact of neurocognitive function on quality of life 5 years after cardiac surgery. Stroke 2001 32 2874 81
7. van Harten AE, Scheeren TW, Absalom AR, A review of postoperative cognitive dysfunction and neuroinflammation associated with cardiac surgery and anaesthesia. Anaesthesia 2012 67 280 93
8. Silbert B, Evered L, Scott DA, McMahon S, Choong P, Ames D, Maruff P, Jamrozik K, Preexisting cognitive impairment is associated with postoperative cognitive dysfunction after hip joint replacement surgery. A nesthesiology 2015 122 1224 34
9. Ritchie K, Carrière I, Ritchie CW, Berr C, Artero S, Ancelin ML, Designing prevention programmes to reduce incidence of dementia: Prospective cohort study of modifiable risk factors. BMJ 2010 341 c3885
10. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH, Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 7 280 92
11. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K, Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010 9 560 74
12. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K, Biological markers of amyloid β-related mechanisms in Alzheimer's disease. Exp Neurol 2010 223 334 46
13. Blennow K, Hampel H, Weiner M, Zetterberg H, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010 6 131 44
14. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009 65 403 13
15. Holtzman DM, CSF biomarkers for Alzheimer's disease: Current utility and potential future use. Neurobiol Aging 2011 32 suppl 1 S4 9
16. Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H, Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 2009 44 579 85
17. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010 67 949 56
18. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K, Cerebrospinal fluid β-Amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003 15 169 76
19. Hogue CW Jr, Hershey T, Dixon D, Fucetola R, Nassief A, Freedland KE, Thomas B, Schechtman K, Preexisting cognitive impairment in women before cardiac surgery and its relationship with C-reactive protein concentrations. Anesth Analg 2006 102 1602 8
20. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K, Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012 8 65 73
21. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH, The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 7 263 9
22. Nelson H, National Adult Reading Test (NART) for the Assessment of Premorbid Intelligence in Patients with Dementia: Test Manual 1992 Windsor, England Psychological Corporation
23. Rasmussen LS, Larsen K, Houx P, Skovgaard LT, Hanning CD, Moller JT, ISPOCD Group; The International Study of Postoperative Cognitive Dysfunction The assessment of postoperative cognitive function. Acta Anaesthesiol Scand 2001 45 275 89
24. Evered LA, Silbert BS, Scott DA, Maruff P, Ames D, Choong PF, Preexisting cognitive impairment and mild cognitive impairment in subjects presenting for total hip joint replacement. A nesthesiology 2011 114 1297 304
25. Morris JC, Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997 9 suppl 1 173 6; discussion 177 8
26. Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, Vellas B, Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. Alzheimers Dement 2011 7 602 610.e2
27. Jorm AF, A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Development and cross-validation. Psychol Med 1994 24 145 53
28. Galasko D, Bennett DA, Sano M, Marson D, Kaye J, Edland SD, Alzheimer's Disease Cooperative Study ADCS Prevention Instrument Project: Assessment of instrumental activities of daily living for community-Dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord 2006 20 4 suppl 3 S152 69
29. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO, Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1982 17 37 49
30. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K, Cerebrospinal fluid β-Amyloid(1-42) in Alzheimer disease: Differences between early-And late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999 56 673 80
31. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E, Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995 26 231 45
32. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, Andreasen N, Blennow K, Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000 285 49 52
33. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelsø C, Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996 67 2013 8
34. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, Edman A, Blennow K, Wallin A, Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord 2009 28 348 56
35. Blennow K, Hampel H, CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003 2 605 13
36. Scott DA, Evered LA, Silbert BS, Cardiac surgery, the brain, and inflammation. J Extra Corpor Technol 2014 46 15 22
37. Abildstrom H, Rasmussen LS, Rentowl P, Hanning CD, Rasmussen H, Kristensen PA, Moller JT, Cognitive dysfunction 1-2 years after non-cardiac surgery in the elderly. ISPOCD group. International Study of Post-Operative Cognitive Dysfunction. Acta Anaesthesiol Scand 2000 44 1246 51
38. Selkoe DJ, Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001 81 741 66
39. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ, Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013 12 207 16
40. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K, Cerebrospinal fluid β-Amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007 78 461 4
41. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E, Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 2007 24 118 24
42. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O, Cerebrospinal fluid levels of β-Amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012 69 98 106
43. Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H, Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 2015 36 297 309
44. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013 5th edition Washington, D.C. American Psychiatric Association
45. Tang JX, Baranov D, Hammond M, Shaw LM, Eckenhoff MF, Eckenhoff RG, Human Alzheimer and inflammation biomarkers after anesthesia and surgery. A nesthesiology 2011 115 727 32
46. Moghekar A, Goh J, Li M, Albert M, O'Brien RJ, Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. Arch Neurol 2012 69 246 50
47. Xie Z, McAuliffe S, Swain CA, Ward SA, Crosby CA, Zheng H, Sherman J, Dong Y, Zhang Y, Sunder N, Burke D, Washicosky KJ, Tanzi RE, Marcantonio ER, Cerebrospinal fluid aβ to tau ratio and postoperative cognitive change. Ann Surg 2013 258 364 9
48. Ji MH, Yuan HM, Zhang GF, Li XM, Dong L, Li WY, Zhou ZQ, Yang JJ, Changes in plasma and cerebrospinal fluid biomarkers in aged patients with early postoperative cognitive dysfunction following total hip-replacement surgery. J Anesth 2013 27 236 42
49. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H, Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 2015 11 58 69